It is also a proven therapeutic target; the FDA has approved the use of pemigatinib, infigratinib and futibatinib for cholangiocarcinoma with FGFR2 fusions and erdafatinib for bladder cancer with FGFR2/3 fusions and FGFR3 mutations. Here, FGFR3 is linked to urinary bladder carcinoma.